BioSpace

Vanda freezes Novartis-originated social anxiety program after late-stage disappointment

While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting.

By BioSpace

1 min read
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights